お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
922775

CAR-T細胞療法市場レビュー

CAR-T Cell Therapy Market Review

出版日: | 発行: Kalorama Information | ページ情報: 英文 59 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
CAR-T細胞療法市場レビュー
出版日: 2019年12月19日
発行: Kalorama Information
ページ情報: 英文 59 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

CAR-T細胞療法は、がん細胞を標的にして破壊するために身体のT細胞を利用する免疫療法の一種です。この治療法は個人に合わせた治療法であり、各患者はがん診断に特化したT細胞を受け取ります。T細胞療法は、患者から既存のT細胞を除去し、それらを実験室で成長および改変させることにより機能します。これらの新しいT細胞には、キメラ抗原受容体(CAR)として知られる特殊な受容体の遺伝子が与えられ、細胞が癌細胞を特異的に攻撃できるようにします。 CAR-T細胞療法は、特に急性リンパ芽球性白血病(ALL)、DLBCL B細胞リンパ腫、多発性骨髄腫の疾患に対して、癌細胞の除去に有効性を示しています。

当レポートでは、CAR-T細胞療法市場について調査し、市場の動向、課題、および近年の発展動向などについて分析しています。

第1章 エグゼクティブサマリー

第2章 CAR-T細胞療法市場

  • FDA承認済みのCAR-T療法:YESCARTAおよびKYMRIAH
  • CAR-T細胞療法市場の動向/課題
  • 最近の市場開発
  • 開発中の主なCAR-T療法
  • CAR-T市場分析

第3章 市場参入企業

  • ABBVIE、INC.
  • AUTOLUS THERAPEUTICS PLC
  • BELLICUM PHARMACEUTICALS, INC.
  • BLUEBIRD BIO, INC.
  • BRISTOL-MYERS SQUIBB COMPANY
  • CARSGEN THERAPEUTICS
  • CELGENE CORPORATION
  • CELLECTIS, INC.
  • CELYAD
  • GILEAD SCIENCES、INC.
  • GLAXOSMITHKLINE
  • GRACELL BIOTECHNOLOGY
  • IMMUNE THERAPEUTICS
  • INNOVATIVE CELLULAR THERAPEUTICS
  • JUNO THERAPEUTICS
  • KITE PHARMA, INC.
  • MUSTANG BIO
  • NOVARTIS INTERNATIONAL AG
  • PFIZER, INC.
  • SORRENTO THERAPEUTICS
  • ZIOPHARM ONCOLOGY,INC
目次
Product Code: 19-099

CAR-T cell therapy is a form of immunotherapy that utilizes the body's own T cells to target and destroy cancer cells. This therapy is a personalized form of treatment, meaning that each patient receives T cells that are geared specifically toward his or her cancer diagnosis. T-cell therapy works by removing existing T cells from a patient and having them grown and modified in a lab. These new T cells are given a gene for a specialized receptor, known as a chimeric antigen receptor (CAR), which allows the cells to specifically attack cancer cells. CAR-T cell therapy has shown effectiveness in eliminating cancer cells, especially for the following diseases:

  • Acute lymphoblastic leukemia (ALL)
  • DLBCL B-cell lymphomas
  • Multiple myeloma

‘CAR-T Cell Therapy Market Review’ discusses CAR-T's impressive revenue growth, which is expected to continue given the effectiveness of the therapy and the projected new users. There are positive factors for the market, though there are limits to growth. Patient volume should increase, though it is likely that the unusually large prices will not sustain over the next five years. The report provides the following market data:

  • CAR-T Market, 2018-2024 ($millions)
  • CAR-T Market Share, 2019 (%)
  • CAR-T Market Regional Breakout, 2019 (%)

‘CAR-T Cell Therapy Market Review’ discusses CAR-T therapy market trends, issues, and recent developments, including the following:

  • Global Cancer Burden
  • Complexity of the CARs Manufacturing Process
  • Diseases Treated with CAR-T
  • Study Shows Yescarta Increases Longevity
  • CRS and Other Side Effects
  • China CAR-T Competition
  • Indian CAR-T Competition
  • "Off-the-Shelf" CAR-T Therapies in Development
  • Competing Therapy in Development

Also noted in the report are selected CAR-T therapies in development, an effort to capture current media coverage of CAR-T trials.

‘CAR-T Cell Therapy Market Review’ notes the activities of many of the major players in the market. The market companies that are covered in the report are the following:

  • AbbVie, Inc.
  • Autolus Therapeutics plc
  • Bellicum Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics
  • Celgene Corporation
  • Cellectis, Inc.
  • Celyad
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Immune Therapeutics
  • Innovative Cellular Therapeutics
  • Juno Therapeutics
  • Kite Pharma, Inc.
  • Mustang Bio
  • Novartis International AG
  • Pfizer, Inc.
  • Sorrento Therapeutics
  • ZIOPHARM Oncology, Inc.

Table of Contents

1: EXECUTIVE SUMMARY

  • INTRODUCTION
  • CAR-T THERAPY MARKET TRENDS, ISSUES, AND RECENT DEVELOPMENTS
  • CAR-T THERAPY MARKET
  • COMPANIES IN THE MARKET

2: CAR-T CELL THERAPY MARKET

  • FDA-APPROVED CAR-T THERAPIES: YESCARTA AND KYMRIAH
    • Yescarta
    • Kymriah
      • Table 2-1: FDA-Approved CAR-T Therapies
  • CAR-T THERAPY MARKET TRENDS / ISSUES
    • Global Cancer Burden
      • Figure 2-1: Global Cancer Incidence Trends, 2010-2040
    • Complexity of the CARs Manufacturing Process
    • Diseases Treated with CAR-T
  • RECENT MARKET DEVELOPMENTS
    • Study Shows Yescarta Increases Longevity
    • CRS and Other Side Effects
    • China CAR-T Competition
    • Indian CAR-T Competition
    • "Off-the-Shelf" CAR-T Therapies in Development
  • A Competing Therapy in Development
  • SELECTED CAR-T THERAPIES IN DEVELOPMENT
    • Table 2-2: Selected CAR-T Therapies in Development
  • KTE-X19
  • liso-cel
  • C-CAR088
  • IBI326 (Innovent) / CT103A (IASO BIO)
  • bb21217
  • MB-107
  • ICTCAR014
  • bb2121
  • JNJ-682284528 (JNJ-4528)
  • CT053
  • MB-101 (IL-13Rα2)
  • MB-108 (oncolytic virus C134)
  • CYAD-01
  • BAFF-R CAR-T
  • MB-105 (PSCA)
  • MB-102 (CD123)
  • MB-103 (HER2)
  • P-BCMA-101
  • LCAR-B38M
  • JCARH125
  • MCARH171
  • CYAD-101
  • MB-106 (CD20)
  • MB-104 (CS1)
  • AMG 119
  • ATA2271
  • AUTO1
  • AUTO3
  • CAR-T MARKET ANALYSIS
    • Figure 2-2: CAR-T Market, 2018-2024 ($millions)
    • Market Share
      • Figure 2-3: CAR-T Market Share, 2019 (%)
    • Regional Breakout
      • Figure 2-4: CAR-T Market Regional Breakout, 2019 (%)

3: COMPANIES IN THE MARKET

  • ABBVIE, INC.
    • Company Summary
    • Scripps Research Institute Deal
    • Tyrosine Kinase Inhibitors Market
  • AUTOLUS THERAPEUTICS PLC
  • BELLICUM PHARMACEUTICALS, INC.
  • BLUEBIRD BIO, INC.
    • Company Summary
    • bb2121
    • bb21217
    • bb2121
  • BRISTOL-MYERS SQUIBB COMPANY
    • Company Summary
    • BMS Acquires Celgene
    • Monoclonal Antibodies Market
    • Cancer Kinase Inhibitor Market
  • CARSGEN THERAPEUTICS
  • CELGENE CORPORATION
    • Company Summary
    • Collaboration with Immatics Biotechnologies
    • Celgene Acquires Juno, Developer of CAR-T and TCR Therapeutics, for $9 Billion
    • Celgene Buys JAK2 Inhibitor Maker
  • CELLECTIS, INC.
    • Pfizer
    • Servier
  • CELYAD
    • CYAD-01
    • CYAD-101
  • GILEAD SCIENCES, INC.
  • GLAXOSMITHKLINE
  • GRACELL BIOTECHNOLOGY
  • IMMUNE THERAPEUTICS
    • CAR-T
  • INNOVATIVE CELLULAR THERAPEUTICS
    • ICTCAR014
  • JUNO THERAPEUTICS
    • Selected CAR-T Therapies in Development
    • Collaboration with Editas Medicine
  • KITE PHARMA, INC.
    • KTE-X19
    • Yescarta
  • MUSTANG BIO
  • NOVARTIS INTERNATIONAL AG
    • Company Summary
    • Kymriah
    • Intellia Therapeutics
    • Other Company Activity
  • PFIZER, INC.
  • SORRENTO THERAPEUTICS
  • ZIOPHARM ONCOLOGY, INC
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.